Structure-Activity Relationship and Biological Investigation of SR18292 (
Adipocytes, Brown
/ drug effects
Animals
Diabetes Mellitus, Type 2
/ drug therapy
Glucagon
/ antagonists & inhibitors
Gluconeogenesis
/ drug effects
Hepatocytes
/ drug effects
Hypoglycemic Agents
/ chemistry
Indoles
/ chemistry
Lipolysis
/ drug effects
Liver Glycogen
/ metabolism
Male
Mice
Mice, Inbred C57BL
PPAR gamma
/ drug effects
Propanols
/ chemistry
Receptors, Adrenergic, beta
/ drug effects
Signal Transduction
/ drug effects
Structure-Activity Relationship
Sympathetic Nervous System
/ drug effects
Journal
Journal of medicinal chemistry
ISSN: 1520-4804
Titre abrégé: J Med Chem
Pays: United States
ID NLM: 9716531
Informations de publication
Date de publication:
28 01 2021
28 01 2021
Historique:
pubmed:
13
1
2021
medline:
24
3
2021
entrez:
12
1
2021
Statut:
ppublish
Résumé
Despite a myriad of available pharmacotherapies for the treatment of type 2 diabetes (T2D), challenges still exist in achieving glycemic control. Several novel glucose-lowering strategies are currently under clinical investigation, highlighting the need for more robust treatments. Previously, we have shown that suppressing peroxisome proliferator-activated receptor gamma coactivator 1-alpha activity with a small molecule (SR18292,
Identifiants
pubmed: 33434430
doi: 10.1021/acs.jmedchem.0c01450
pmc: PMC7869975
mid: NIHMS1663551
doi:
Substances chimiques
Hypoglycemic Agents
0
Indoles
0
Liver Glycogen
0
PPAR gamma
0
Propanols
0
Receptors, Adrenergic, beta
0
SR18292
0
Glucagon
9007-92-5
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
980-990Subventions
Organisme : NIDDK NIH HHS
ID : R01 DK117655
Pays : United States
Organisme : NIDA NIH HHS
ID : HHSN271201800023C
Pays : United States
Références
J Med Chem. 1986 Aug;29(8):1524-7
pubmed: 2874227
Mini Rev Med Chem. 2016;16(1):40-54
pubmed: 26471965
Nat Rev Endocrinol. 2014 Mar;10(3):143-56
pubmed: 24393785
Cell Metab. 2011 Jul 6;14(1):9-19
pubmed: 21723500
Exp Mol Med. 2016 Mar 11;48:e218
pubmed: 26964834
Nature. 2001 Sep 13;413(6852):131-8
pubmed: 11557972
Am J Med. 2013 Sep;126(9 Suppl 1):S10-20
pubmed: 23953074
Nature. 2003 May 29;423(6939):550-5
pubmed: 12754525
J Clin Invest. 1992 Oct;90(4):1323-7
pubmed: 1401068
Adv Nutr. 2012 May 01;3(3):286-94
pubmed: 22585902
Nature. 2005 Mar 3;434(7029):113-8
pubmed: 15744310
Cell Metab. 2006 Jun;3(6):429-38
pubmed: 16753578
Diabetol Metab Syndr. 2013 Feb 15;5(1):6
pubmed: 23415113
Cell Metab. 2010 Jan;11(1):23-34
pubmed: 20074525
Diabetes. 1989 May;38(5):550-7
pubmed: 2653926
Diabetes Obes Metab. 2011 Jan;13(1):7-18
pubmed: 21114598
Nature. 2001 Sep 13;413(6852):179-83
pubmed: 11557984
Nature. 2012 Dec 13;492(7428):215-20
pubmed: 23235874
Annu Rev Nutr. 2007;27:79-101
pubmed: 17313320
Cell. 2017 Mar 23;169(1):148-160.e15
pubmed: 28340340
Diabetes. 2000 Dec;49(12):2063-9
pubmed: 11118008
Mol Aspects Med. 2015 Dec;46:21-33
pubmed: 26549348
Bioorg Med Chem Lett. 2007 Oct 15;17(20):5600-4
pubmed: 17804228
Mol Cell. 2012 Dec 28;48(6):900-13
pubmed: 23142079